NOV 23, 2020
University of Louisville’s Brown Cancer Center Embraces Immuno-Oncology Developed at NCI: Some Patients See Dramatic Results
".. six months to live..stage four lung cancer... sought out a second opinion with Dr. Jason Chesney at the University of Louisville Health’s James Graham Brown Cancer Center.
".. has eliminated six of Mr. Burton’s seven tumors.. I’m hoping at my next scan it will be gone.” This near “game changer”
"sponsored by Iovance Biotherapeutics..
"The basket trial is a Phase 2 study with 30 patients with CCR5+ locally advanced or metastatic solid tumors. Leronlimab will be administered subcutaneously as a weekly dose of 350 mg.
..including melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other (CCR5 receptor=lung cancer)
NOV 23, 2020 University of Louisville’s Brown Cancer Center Embraces Immuno-Oncology Developed at NCI: Some Patients See Dramatic Results
".. six months to live..stage four lung cancer... sought out a second opinion with Dr. Jason Chesney at the University of Louisville Health’s James Graham Brown Cancer Center. ".. has eliminated six of Mr. Burton’s seven tumors.. I’m hoping at my next scan it will be gone.” This near “game changer” "sponsored by Iovance Biotherapeutics..
https://www.trialsitenews.com/university-of-louisvilles-brown-cancer-center-embraces-immuno-oncology-developed-at-nci-some-patients-see-dramatic-results/
"The basket trial is a Phase 2 study with 30 patients with CCR5+ locally advanced or metastatic solid tumors. Leronlimab will be administered subcutaneously as a weekly dose of 350 mg. ..including melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other (CCR5 receptor=lung cancer)
https://www.cytodyn.com/newsroom/press-releases/detail/382/cytodyn-files-a-phase-2-basket-trial-with-leronlimab-pro